Alliance for Transformative Action on Climate and Health Restructured at General Meeting
The Alliance for Transformative Action on Climate and Health (ATACH) recently held a virtual general meeting to announce a comprehensive restructuring aimed at enhancing its responsiveness to the climate crisis…
INTerpath-009 Trial Expands V940 Clinical Program, Targeting Earlier Cancer Stages
Merck (NYSE: MRK), known as MSD in markets outside the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), have announced the launch of INTerpath-009, a pivotal Phase 3 randomized…
AbbVie Acquires Aliada Therapeutics to Strengthen Alzheimer’s and Neuroscience Commitment
AbbVie (NYSE: ABBV) has announced a definitive agreement to acquire Aliada Therapeutics, a biotechnology firm focused on developing therapies using innovative blood-brain barrier (BBB)-crossing technology aimed at treating complex central…
Astellas Updates on Marketing Authorization Application for Avacincaptad Pegol (ACP) in the EU
Astellas Pharma Inc. (TSE: 4503; President and CEO: Naoki Okamura) announced today its decision to withdraw the marketing authorization application for avacincaptad pegol intravitreal solution (ACP) from the European Medicines…
Walgreens Expands Virtual Healthcare to 30 States, Adds Lab Tests and STD Treatments
Walgreens is expanding its virtual healthcare service to enhance access for patients nationwide. As of October 1, Walgreens Virtual Healthcare is now available in 30 states, a significant increase from…
Merck and Moderna Launch Phase 3 Trial of V940 and KEYTRUDA® Combo in Non-Small Cell Lung Cancer
Merck (NYSE: MRK), also known as MSD outside the U.S. and Canada, and Moderna, Inc. (Nasdaq: MRNA), announced the launch of INTerpath-009, a Phase 3 randomized clinical trial investigating V940…
Michael McDonnell, EVP & CFO, to Retire in February 2025
Biogen Inc. (Nasdaq: BIIB) announced today that Michael McDonnell, Executive Vice President and Chief Financial Officer, will retire from his role on February 28, 2025. Upon his retirement, Robin Kramer,…
WuXi Biologics Introduces WuXia™ RidGS Platform for Antibiotic-Free Cell Line Development
WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has launched WuXia™ RidGS, an advanced glutamine synthetase (GS)-knockout Chinese hamster ovary (CHO) expression system platform. Designed…
Lupin Prioritizes Development of Inhalers with Eco-Friendly, Low Global Warming Propellants
Lupin Limited, a global leader in pharmaceuticals, has announced a strategic shift toward developing respiratory inhalers with propellants that have near-zero global warming potential (GWP). This initiative aims to provide…
Odyssey Therapeutics to Present Data on OD-07656 at ACG Annual Scientific Meeting 2024
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on transforming care for patients with autoimmune and inflammatory diseases, has announced the presentation of new translational data on its receptor-interacting protein…
Judo Bio Reveals Data on Gene Silencing via Receptor-Mediated Oligonucleotide Delivery in the Kidney
Judo Bio, a biotechnology company focused on developing oligonucleotide medicines for kidney delivery, has announced the presentation of preclinical data demonstrating a mechanism for the uptake and trafficking of ligand-siRNA…
Novartis Oral Fabhalta® Shows Sustained Benefits in One-Year Phase III C3G Trial
Novartis presented promising 12-month results from its Phase III APPEAR-C3G study at the 2024 American Society of Nephrology (ASN) Kidney Week. These findings show that patients with C3 glomerulopathy (C3G)…